124 related articles for article (PubMed ID: 31892980)
1. Aberrant CDK9 expression within chordoma tissues and the therapeutic potential of a selective CDK9 inhibitor LDC000067.
Shen S; Dean DC; Yu Z; Hornicek F; Kan Q; Duan Z
J Cancer; 2020; 11(1):132-141. PubMed ID: 31892980
[No Abstract] [Full Text] [Related]
2. Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor.
Albert TK; Rigault C; Eickhoff J; Baumgart K; Antrecht C; Klebl B; Mittler G; Meisterernst M
Br J Pharmacol; 2014 Jan; 171(1):55-68. PubMed ID: 24102143
[TBL] [Abstract][Full Text] [Related]
3. Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in ovarian cancer.
Wang J; Dean DC; Hornicek FJ; Shi H; Duan Z
FASEB J; 2019 May; 33(5):5990-6000. PubMed ID: 30726104
[TBL] [Abstract][Full Text] [Related]
4. Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma.
Ma H; Seebacher NA; Hornicek FJ; Duan Z
EBioMedicine; 2019 Jan; 39():182-193. PubMed ID: 30579871
[TBL] [Abstract][Full Text] [Related]
5. T-LAK cell-originated protein kinase (TOPK) is a Novel Prognostic and Therapeutic Target in Chordoma.
Thanindratarn P; Dean DC; Nelson SD; Hornicek FJ; Duan Z
Cell Prolif; 2020 Oct; 53(10):e12901. PubMed ID: 32960500
[TBL] [Abstract][Full Text] [Related]
6. Cyclin-dependent kinase 12 (CDK12) in chordoma: prognostic and therapeutic value.
Thanindratarn P; Dean DC; Feng W; Wei R; Nelson SD; Hornicek FJ; Duan Z
Eur Spine J; 2020 Dec; 29(12):3214-3228. PubMed ID: 32691223
[TBL] [Abstract][Full Text] [Related]
7. Expression and Therapeutic Potential of SOX9 in Chordoma.
Chen H; Garbutt CC; Spentzos D; Choy E; Hornicek FJ; Duan Z
Clin Cancer Res; 2017 Sep; 23(17):5176-5186. PubMed ID: 28606919
[No Abstract] [Full Text] [Related]
8. CMTM3 suppresses chordoma progress through EGFR/STAT3 regulated EMT and TP53 signaling pathway.
Yuan W; Wei F; Ouyang H; Ren X; Hang J; Mo X; Liu Z
Cancer Cell Int; 2021 Sep; 21(1):510. PubMed ID: 34560882
[TBL] [Abstract][Full Text] [Related]
9. Proteomics and phosphoproteomics of chordoma biopsies reveal alterations in multiple pathways and aberrant kinases activities.
Hang J; Ouyang H; Wei F; Zhong Q; Yuan W; Jiang L; Liu Z
Front Oncol; 2022; 12():941046. PubMed ID: 36248973
[TBL] [Abstract][Full Text] [Related]
10. Targeting regulation of cyclin dependent kinase 9 as a novel therapeutic strategy in synovial sarcoma.
Li X; Seebacher NA; Xiao T; Hornicek FJ; Duan Z
J Orthop Res; 2019 Feb; 37(2):510-521. PubMed ID: 30488489
[TBL] [Abstract][Full Text] [Related]
11. Targeting CDK9: A novel biomarker in the treatment of endometrial cancer.
He S; Fang X; Xia X; Hou T; Zhang T
Oncol Rep; 2020 Nov; 44(5):1929-1938. PubMed ID: 32901849
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of CDK9 exhibits anticancer activity in hepatocellular carcinoma cells via targeting ribonucleotide reductase.
Lin JC; Liu TP; Chen YB; Huang TS; Chen TY; Yang PM
Toxicol Appl Pharmacol; 2023 Jul; 471():116568. PubMed ID: 37245555
[TBL] [Abstract][Full Text] [Related]
13. Targeting cyclin-dependent kinase 9 sensitizes medulloblastoma cells to chemotherapy.
Song H; Bhakat R; Kling MJ; Coulter DW; Chaturvedi NK; Ray S; Joshi SS
Biochem Biophys Res Commun; 2019 Dec; 520(2):250-256. PubMed ID: 31594641
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of CDK9 induces apoptosis and potentiates the effect of cisplatin in hypopharyngeal carcinoma cells.
Cao S; Yu Y; Chen S; Lei D; Wang S; Pan X; Peng J
Biochem Biophys Res Commun; 2017 Jan; 482(4):536-541. PubMed ID: 27847320
[TBL] [Abstract][Full Text] [Related]
15. CDK4 expression in chordoma: A potential therapeutic target.
Liu T; Shen JK; Choy E; Zhang Y; Mankin HJ; Hornicek FJ; Duan Z
J Orthop Res; 2018 Jun; 36(6):1581-1589. PubMed ID: 29194728
[TBL] [Abstract][Full Text] [Related]
16. Cyclin-dependent kinase 9 promotes cervical cancer development via AKT2/p53 pathway.
Xu J; Xu S; Fang Y; Chen T; Xie X; Lu W
IUBMB Life; 2019 Mar; 71(3):347-356. PubMed ID: 30536701
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Significance of Cyclin E1 Expression in Patients With Chordoma: A Clinicopathological and Immunohistochemical Study.
Wei R; Dean DC; Thanindratarn P; Hornicek FJ; Guo W; Duan Z
Front Oncol; 2020; 10():596330. PubMed ID: 33282745
[TBL] [Abstract][Full Text] [Related]
18. Establishment and characterization of a chordoma cell line from the tissue of a patient with dedifferentiated-type chordoma.
Kim JY; Lee J; Koh JS; Park MJ; Chang UK
J Neurosurg Spine; 2016 Nov; 25(5):626-635. PubMed ID: 27314550
[TBL] [Abstract][Full Text] [Related]
19. Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma.
Veeranki OL; Tong Z; Dokey R; Mejia A; Zhang J; Qiao Y; Singh PK; Katkhuda R; Mino B; Tailor R; Canales JR; Bassett R; Ajani J; Wu JY; Kopetz S; Blum M; Hofstetter W; Tetzlaff M; Krishnan S; Lin SH; Maru D
Oncotarget; 2019 Jul; 10(45):4703-4718. PubMed ID: 31384397
[TBL] [Abstract][Full Text] [Related]
20. Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor.
Lim SL; Xu L; Han BC; Shyamsunder P; Chng WJ; Koeffler HP
PLoS One; 2020; 15(6):e0232068. PubMed ID: 32559187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
